Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.

BJU international·2026
Same author

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).

The Journal of urology·2026
Same author

Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant.

Journal of the National Cancer Institute·2025

Related Experiment Video

Updated: Jun 19, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostatic specific antigen for prostate cancer detection.

Lucas Nogueira1, Renato Corradi, James A Eastham

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 , USA. nogueirl@mskcc.org

International Braz J Urol : Official Journal of the Brazilian Society of Urology
|October 29, 2009
PubMed
Summary
This summary is machine-generated.

Prostate-specific antigen (PSA) testing significantly reduced advanced prostate cancer and mortality. However, its low specificity leads to over-detection and over-treatment, prompting research into improved PSA screening methods.

More Related Videos

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jun 19, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

  • Urology
  • Oncology
  • Biomarker Research

Background:

  • Prostate-specific antigen (PSA) testing, utilized since 1994, has transformed prostate cancer (PC) diagnosis and management.
  • PSA screening has dramatically decreased advanced-stage disease and mortality rates.
  • However, PSA testing has limitations in specificity, leading to over-detection and over-treatment of indolent cancers.

Purpose of the Study:

  • To review the history and evidence for PSA testing in prostate cancer detection.
  • To explore variations in PSA measurement as adjuncts for improved screening accuracy.
  • To discuss the clinical application and ongoing debate surrounding PSA testing.

Main Methods:

  • Review of historical data and scientific literature on PSA testing and its variations.
  • Analysis of the impact of PSA screening on prostate cancer incidence and mortality.
  • Examination of different PSA measurement techniques and their diagnostic utility.

Main Results:

  • PSA screening led to a substantial decrease in advanced PC and a 32.5% reduction in mortality by 2003.
  • Increased detection resulted in more localized tumors and a 75% reduction in metastatic disease presentation.
  • Variations like free PSA, PSA density, and PSA velocity show promise for enhancing screening specificity.

Conclusions:

  • PSA testing has been pivotal in reducing prostate cancer mortality and advanced disease.
  • Limitations in PSA specificity necessitate the exploration of adjunct markers for more accurate screening.
  • Further research into PSA variations aims to optimize prostate cancer detection while minimizing over-treatment.